01672.HK
Ascletis Pharma Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 10.09
−2.32%Year over year
Reported trailing growth
- Revenue
- -95.4%
- EBITDA
- -57.7%
- EBIT
- -63.3%
- EPS
- -84.1%
- Free cash flow
- +27.9%
- Operating cash flow
- +26.9%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- +38.7%
- EPS
- +53.1%
Three-year CAGR
- Revenue
- -66.5%
- EBITDA
- -20.8%
- EBIT
- -63.8%
- Net income
- -19.6%
- EPS
- -23.3%
- Free cash flow
- +3.8%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026